"IC is a frustrating disease for patients because, to this point, there is no accurate way of diagnosing the condition. Patients undergo a variety of tests to rule out other diseases, all while experiencing significant pain and discomfort. Only after these tests come back negative, can a doctor make the diagnosis of IC," said Michael Chancellor, M.D., professor, department of urology, University of Pittsburgh School of Medicine.
"Finding a marker for IC can not only make developing an early test for IC possible, but it can lead to new targeted molecular therapies for the condition," said Fernando de Miguel, Ph.D., assistant professor of urology at Pitt's School of Medicine.
In the first study, titled "Identification of Nuclear Proteins in the Chronic Cystitic Rat Model" (abstract 69), researchers used a proteomic approach to identify specific markers related to IC. By comparing protein expression in the bladder tissue of two animal models of IC to expression in the tissue of a normal animal, the researchers found three nuclear proteins that were unique to the animals with IC. Using protein mass fingerprinting, the proteins were identified as transgelin (SM-22), ras suppressor protein (RSU-1) and GAPDH.
In the second study, titled "Time-point study of the Regulation of Nuclear Protein SM-22 (Transgelin) in the Rat Cystitis Model" (abstract 80), the researchers expanded their investigation into the expression of SM-22 in both normal